查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1828149

2025年神經調節全球市場報告

Neuromodulation Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，神經調節市場規模強勁成長，從2024年的69.6億美元增加至2025年的76.2億美元，複合年成長率達9.5%。預測期內的成長可歸因於慢性病患病率的上升、臨床證據和研究、患者對非侵入性治療的需求、政府舉措和資金投入、適應症的擴大、合作研究以及夥伴關係的建立。

預計未來幾年神經調節市場規模將快速成長，到2029年將達到115.7億美元，複合年成長率為11.0%。預測期內的成長可歸因於設備小型化、老齡化社會對神經系統疾病的關注度增加、精神病學應用的擴展、以患者為中心的治療方法以及全球醫療保健可及性的提高。預測期內的主要趨勢包括人工智慧 (AI) 的整合、技術進步、非侵入性神經調節技術、閉合迴路神經調節系統、適應症的擴展以及無線和穿戴式神經調節設備。

神經調節是指透過電刺激或藥理方法直接針對特定的神經活動。它是一種緩解疼痛的可逆方法。

神經調節技術主要分為體內和體外兩種。體內神經調節是指在目標神經附近植入電極並傳送低壓電流。生物材料包括聚合物、金屬和陶瓷材料。這些技術用於治療多種疾病，包括慢性疼痛、尿失禁和大便失禁、偏頭痛、下背痛、帕金森氏症、癲癇、震顫和憂鬱症。它們在醫院、診所和家庭醫療保健等各種環境中都有應用。

2025年春季，美國關稅上調及其引發的貿易摩擦對醫療設備產業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰使情況更加複雜，因為由於關稅而更換供應商通常需要重新認證醫療設備，導致市場准入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供神經調節市場統計數據，例如全球市場規模、區域佔有率、神經調節市場佔有率的競爭對手、詳細的神經調節細分市場、市場趨勢以及神經調節行業的商機，為您提供在神經調節行業取得成功所需的數據。本神經調節市場研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供全面的觀點，滿足您的所有需求。

未來五年11.0%的成長率預測，較我們先前對該市場的預測略有下降0.3%。這一下降主要源自於美國與其他國家之間關稅的影響。由於互惠關稅以及日益加劇的貿易緊張局勢和限制對全球經濟和貿易的負面影響，其影響將更加廣泛。

神經系統疾病的日益普及是推動神經調節市場成長的關鍵因素。這些疾病包括影響大腦、神經和脊髓的各種問題。神經調節干預為管理和調節各種神經系統疾病（包括阿茲海默症、帕金森氏症和癲癇）提供了一種有前途的方法。歐洲腦理事會於 2022 年 4 月發布的一份報告顯示，全球整體有 600 多種神經系統疾病和近 300 種精神疾病，5,000 萬人患有阿茲海默症和其他失智症。癲癇影響全球 6500 萬人，凸顯了神經系統疾病的重大影響。預計到 2050 年，歐洲失智症患者的數量將從 1,050 萬大幅增加到 1,870 萬，這意味著神經調節將在解決這一日益嚴重的健康問題中發揮關鍵作用。

預計未來幾年，不斷成長的醫療保健支出將推動神經調節市場的成長。醫療保健支出包括分配給醫療保健及相關活動（例如醫療服務提供、公共和私人醫療保險、健康研究以及公共衛生活動）的總資金。不斷成長的支出將支持神經系統疾病新治療方法和診斷方法的開發和應用，並為創新神經調節技術的研發、療效、安全性和標靶性提供額外資金。例如，2022年11月，總部位於美國的非營利組織加拿大衛生資訊研究所報告稱，2022年醫療保健支出將增加0.8%，達到3,310億美元，而2021年的增幅為7.6%。因此，不斷成長的醫療保健支出正在推動神經調節市場的成長。

技術進步是推動神經調節市場發展的關鍵趨勢。該領域的主要企業正致力於開發創新的技術解決方案，以提升其市場地位。例如，2024 年 1 月，專注於數位自我神經調節療法的以色列公司 GrayMatters Health 宣布推出 Prism，這是一種經 FDA 批准的用於治療創傷後壓力症候群 (PTSD) 的新型自我神經調節療法。這款尖端設備整合了腦電圖帽和軟體，可幫助患者透過神經回饋管理情緒反應。該技術旨在透過為患者提供主動管理症狀的工具來補充傳統的心理治療和藥物治療。此外，2022 年 12 月，美國醫療設備和醫療保健公司雅培實驗室宣布推出 Eterna 脊髓刺激 (SCS) 系統，這是目前最小的可植入、可充電脊髓刺激設備。 Eterna SCS 採用雅培專利的低劑量 BurstDR 刺激技術，是唯一獲得最高等級臨床證據（1A 證據）支持的 SCS 波形創新技術，與傳統波形技術相比，疼痛緩解效果提高了 23%。

主要企業正專注於推出具有先進功能的下一代設備，例如植入式脈衝產生器 (IPG)，以獲得競爭優勢。 Barostim Neo2 IPG 就是其中一個例子，它是 CVRx 用於治療心臟衰竭領域對患者友好、耐用且高效的解決方案的追求。

2022年3月，美國知名醫療設備製造商ElectroMedical Products International, Inc. (EPI) 收購了Pulvinar Neuro LLC，具體金額未揭露。此次策略性收購使EPI能夠進一步推進其取得專利的技術，尤其是經顱交流電刺激(tACS)、增強型個人化回饋刺激以及擴展的雲端數位療法，用於治療精神和神經系統疾病。 Pulvinar Neuro是一家總部位於美國的神經科技公司，專注於利用最尖端科技支持神經科學研究，與EPI推動該領域醫療創新的目標完美契合。

神經調節市場的主要企業包括雅培實驗室、Soterix Medical Inc.、波士頓科學公司、美敦力公司、Synapse Biomedical Inc.、Nevro Corp、Neuropace Inc.、LivaNova PLC、Neurosigma Inc.、Neuronetics Inc.、Bioness Inc.、Aleva Neurooxyutics SASmerat Corporation. Ltd、Otolith Labs Inc.、Machine Medicine Inc.、Inbrain Neuroelectronics SAS、Pixium Vision SA、Neuromod Devices Limited、Cognito Therapeutics Inc.、PathMaker Neurosystems Inc.、Dignify Therapeutics Inc. , Omron Corporation。

2024年神經調節市場最大的地區是北美。神經調節市場報告涵蓋的地區包括亞太地區、西歐、東歐、北美、南美、中東和非洲。

神經調節市場報告涵蓋的國家有澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國、美國、加拿大、義大利、西班牙

神經調節市場涵蓋營業單位透過治療骨盆腔疾病和失禁的薦椎神經刺激、治療巴金森氏症的深部腦刺激 (DBS) 以及治療缺血性疾病（心絞痛、周邊血管疾病）的脊髓刺激產生的收益。市場價值包括服務提供者銷售或包含在服務產品中的相關商品的價值。僅包括企業之間交易或銷售給最終消費者的商品和服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球神經調節：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球神經調節市場：成長率分析
  • 全球神經調節市場表現：規模與成長，2019-2024
  • 全球神經調節市場預測：規模與成長，2024-2029，2034
  • 全球神經調節：總目標市場（TAM）

第6章 市場細分

  • 全球神經調節市場（按技術、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 內部神經調節
  • 外部神經調節（非侵入性）
  • 全球神經調節市場（按生醫材料、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 聚合物生醫材料
  • 金屬生醫材料
  • 陶瓷生醫材料
  • 全球神經調節市場的應用、表現和預測，2019-2024 年、2024-2029 年、2034 年
  • 慢性疼痛
  • 尿失禁/大便失禁
  • 偏頭痛
  • 故障恢復綜合症
  • 帕金森氏症
  • 癲癇
  • 震顫
  • 憂鬱症
  • 其他用途
  • 全球神經調節市場（按最終用戶、績效和預測），2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 診所
  • 家庭醫療保健
  • 全球神經調節市場：按內部神經調節細分，按類型、表現和預測，2019-2024 年、2024-2029 年、2034 年
  • 植入式裝置
  • 椎管內藥物輸送系統
  • 全球神經調節市場：按外部神經調節（非侵入性）細分，類型，表現和預測，2019-2024 年、2024-2029 年、2034 年
  • 經顱磁刺激（TMS）
  • 經顱直流電刺激（tDCS）
  • 經皮電刺激（TENS）
  • 周邊神經刺激（PNS）

第7章 區域和國家分析

  • 全球神經調節市場：按地區、績效和預測，2019-2024 年、2024-2029 年、2034 年
  • 全球神經調節市場：依國家、表現及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 神經調節市場：競爭格局
  • 神經調節市場：公司簡介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Soterix Medical Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • Synapse Biomedical Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Nevro Corp
  • Neuropace Inc.
  • LivaNova PLC
  • Neurosigma Inc.
  • Neuronetics Inc.
  • Bioness Inc.
  • Aleva Neurotherapeutics SA
  • Integer Holdings Corporation
  • ReShape Lifesciences Inc.
  • Inspire Medical Systems Inc.
  • Bioventus LLC
  • Saluda Medical Pty Ltd
  • Otolith Labs Inc.
  • Machine Medicine Inc.
  • Inbrain Neuroelectronics SAS

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029 神經調節市場：提供新機會的國家
  • 2029 神經調節市場：細分領域帶來新機會
  • 2029 神經調節市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r24363u

Neuromodulation refers to the adjustment of nerve activity through electrical or pharmacological means, directly targeting specific areas. It's a reversible method employed to alleviate pain.

The primary technologies in neuromodulation include internal and external methods. Internal neuromodulation involves implanting an electrode near a targeted nerve and administering a low-voltage electric current. Biomaterials used encompass polymeric, metallic, and ceramic materials. These technologies are applied in treating various conditions such as chronic pain, urinary and fecal incontinence, migraine, failed back syndrome, Parkinson's disease, epilepsy, tremor, depression, and more. They find use across multiple settings including hospitals, clinics, and home healthcare environments.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The neuromodulation market research report is one of a series of new reports from The Business Research Company that provides neuromodulation market statistics, including the neuromodulation industry's global market size, regional shares, competitors with a neuromodulation market share, detailed neuromodulation market segments, market trends, and opportunities, and any further data you may need to thrive in the neuromodulation industry. This neuromodulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neuromodulation market size has grown strongly in recent years. It will grow from $6.96 billion in 2024 to $7.62 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to rising prevalence of chronic disorders, clinical evidence and research, patient demand for non-invasive therapies, government initiatives and funding, expansion of indications, collaborations and partnerships.

The neuromodulation market size is expected to see rapid growth in the next few years. It will grow to $11.57 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to miniaturization of devices, focus on neurological disorders in aging population, expanded applications in psychiatry, patient-centric approaches, global expansion of healthcare access. Major trends in the forecast period include integration of artificial intelligence (ai), advancements in technology, non-invasive neuromodulation techniques, closed-loop neuromodulation systems, expansion of indications, wireless and wearable neuromodulation devices.

The forecast of 11.0% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through increased duties on rechargeable battery systems from China, raising costs for spinal cord stimulators and affecting chronic pain management treatment options.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of neurological disorders stands as a significant driver for the growth of the neuromodulation market. These disorders encompass a wide range of issues affecting the brain, nerves, and spinal cord. Neuromodulation interventions offer promising avenues for managing and regulating various neurological conditions, including Alzheimer's, Parkinson's, and epilepsy. Reports from the European Brain Council in April 2022 highlighted over 600 neurological diseases and nearly 300 psychiatric conditions globally, with 50 million individuals affected by Alzheimer's and other dementias. Epilepsy, affecting 65 million people worldwide, underscores the substantial impact of neurological disorders. Projections indicate a substantial rise in dementia cases in Europe, from 10.5 million to 18.7 million by 2050, signifying the pivotal role of neuromodulation in addressing these escalating health concerns.

Increasing healthcare expenditures are projected to drive the growth of the neuromodulation market in the coming years. Healthcare expenditure encompasses the total funds allocated for health care and related activities, including health services provision, public and private health insurance, health research, and public health initiatives. Rising expenditures support the development and adoption of new therapies and diagnostic methods for neurological disorders, and they also provide additional funding for research into innovative neuromodulation technologies, enhancing their efficacy, safety, and targeting capabilities. For example, in November 2022, the Canadian Institute for Health Information, a not-for-profit organization based in the U.S., reported that healthcare expenditure increased by 0.8% to reach $331 billion in 2022, compared to 7.6% in 2021. Thus, the rising healthcare expenditure is fueling the growth of the neuromodulation market.

Technological advancements are a significant trend gaining traction in the neuromodulation market. Leading companies in this sector are concentrating on developing innovative technological solutions to enhance their market position. For instance, in January 2024, GrayMatters Health, an Israel-based firm focused on digital self-neuromodulation therapies, introduced a new FDA-cleared self-neuromodulation therapy for PTSD called Prism. This cutting-edge device integrates an EEG cap with software to assist patients in learning to manage their emotional responses through neurofeedback. The technology aims to complement traditional psychotherapy and pharmacotherapy by equipping patients with tools to actively manage their symptoms. Additionally, in December 2022, Abbott Laboratories, a U.S.-based medical devices and healthcare company, unveiled the Eterna spinal cord stimulation (SCS) system, which is the smallest implantable, rechargeable spinal cord stimulator available. Eterna SCS utilizes Abbott's patented low-dose BurstDR stimulation, the only SCS waveform innovation backed by the highest level of clinical evidence (1A evidence), demonstrating a 23% greater pain relief compared to conventional waveform technology.

Major players in the neuromodulation market are focusing on introducing next-generation devices with advanced features, such as the implantable pulse generator (IPG), to gain a competitive edge. For example, CVRx's November 2022 launch of the Barostim Neo2 IPG, an upgraded version of its neuromodulation device for heart failure treatment, exemplifies this pursuit. With improved efficiency, reduced size, and enhanced design facilitating easier implantation, the Barostim Neo2 retains the clinically proven Barostim therapy, emphasizing the drive towards patient-friendly, durable, and efficient solutions in neuromodulation.

In March 2022, Electromedical Products International Inc (EPI), a prominent US-based medical device manufacturer, completed the acquisition of Pulvinar Neuro LLC for an undisclosed sum. This strategic acquisition empowers EPI to further its progress in advancing patented technologies, notably transcranial alternating current stimulation (tACS), enhancing personalized feedback stimulation, and expanding its cloud-enabled digital therapeutics for psychiatric and neurological conditions. Pulvinar Neuro, a US-based neurotechnology company, specializes in leveraging cutting-edge technologies to support neuroscience research, aligning seamlessly with EPI's objectives in advancing medical innovation in this domain.

Major companies operating in the neuromodulation market include Abbott Laboratories, Soterix Medical Inc., Boston Scientific Corporation, Medtronic plc, Synapse Biomedical Inc., Nevro Corp, Neuropace Inc., LivaNova PLC, Neurosigma Inc., Neuronetics Inc., Bioness Inc., Aleva Neurotherapeutics S.A., Integer Holdings Corporation, ReShape Lifesciences Inc., Inspire Medical Systems Inc., Bioventus LLC, Saluda Medical Pty Ltd, Otolith Labs Inc., Machine Medicine Inc., Inbrain Neuroelectronics SAS, Pixium Vision SA, Neuromod Devices Limited, Cognito Therapeutics Inc., PathMaker Neurosystems Inc., Dignify Therapeutics Inc., Neuronoff ApS, Neuros Medical Inc., Fisher & Paykel Healthcare Corporation Limited, Koninklijke Philips N.V., Magic Leap Inc., Omron Corporation

North America was the largest region in the neuromodulation market in 2024. The regions covered in the neuromodulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the neuromodulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The neuromodulation market includes revenues earned by entities through sacral nerve stimulation for pelvic disorders and incontinence, deep brain stimulation (DBS) treatment for Parkinson's disease, and spinal cord stimulation for ischemic disorders (angina, peripheral vascular disease). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuromodulation Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuromodulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuromodulation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neuromodulation market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Technology: Internal Neuromodulation; External Neuromodulation (Non-invasive)
  • 2) By Biomaterial: Polymeric Biomaterial; Metallic Biomaterial; Ceramic Biomaterial
  • 3) By Application: Chronic Pain; Urinary And Fecal Incontinence; Migraine; Failed Back Syndrome; Parkinson Disease; Epilepsy; Tremor; Depression; Other Applications
  • 4) By End-User: Hospitals; Clinics; Home Healthcare
  • Subsegments:
  • 1) By Internal Neuromodulation: Implantable Devices; Intrathecal Drug Delivery Systems
  • 2) By External Neuromodulation (Non-invasive): Transcranial Magnetic Stimulation (TMS); Transcranial Direct Current Stimulation (tDCS); Transcutaneous Electrical Nerve Stimulation (TENS); Peripheral Nerve Stimulation (PNS)
  • Companies Mentioned: Abbott Laboratories; Soterix Medical Inc.; Boston Scientific Corporation; Medtronic plc; Synapse Biomedical Inc.; Nevro Corp; Neuropace Inc.; LivaNova PLC; Neurosigma Inc.; Neuronetics Inc.; Bioness Inc.; Aleva Neurotherapeutics S.A.; Integer Holdings Corporation; ReShape Lifesciences Inc.; Inspire Medical Systems Inc.; Bioventus LLC; Saluda Medical Pty Ltd; Otolith Labs Inc.; Machine Medicine Inc.; Inbrain Neuroelectronics SAS; Pixium Vision SA; Neuromod Devices Limited; Cognito Therapeutics Inc.; PathMaker Neurosystems Inc.; Dignify Therapeutics Inc.; Neuronoff ApS; Neuros Medical Inc.; Fisher & Paykel Healthcare Corporation Limited; Koninklijke Philips N.V.; Magic Leap Inc.; Omron Corporation
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neuromodulation Market Characteristics

3. Neuromodulation Market Trends And Strategies

4. Neuromodulation Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Neuromodulation Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Neuromodulation PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Neuromodulation Market Growth Rate Analysis
  • 5.4. Global Neuromodulation Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Neuromodulation Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Neuromodulation Total Addressable Market (TAM)

6. Neuromodulation Market Segmentation

  • 6.1. Global Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Internal Neuromodulation
  • External Neuromodulation (Non-invasive)
  • 6.2. Global Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymeric Biomaterial
  • Metallic Biomaterial
  • Ceramic Biomaterial
  • 6.3. Global Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chronic Pain
  • Urinary And Fecal Incontinence
  • Migraine
  • Failed Back Syndrome
  • Parkinson Disease
  • Epilepsy
  • Tremor
  • Depression
  • Other Applications
  • 6.4. Global Neuromodulation Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Home Healthcare
  • 6.5. Global Neuromodulation Market, Sub-Segmentation Of Internal Neuromodulation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Implantable Devices
  • Intrathecal Drug Delivery Systems
  • 6.6. Global Neuromodulation Market, Sub-Segmentation Of External Neuromodulation (Non-invasive), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Transcranial Magnetic Stimulation (TMS)
  • Transcranial Direct Current Stimulation (tDCS)
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Peripheral Nerve Stimulation (PNS)

7. Neuromodulation Market Regional And Country Analysis

  • 7.1. Global Neuromodulation Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Neuromodulation Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neuromodulation Market

  • 8.1. Asia-Pacific Neuromodulation Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neuromodulation Market

  • 9.1. China Neuromodulation Market Overview
  • 9.2. China Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neuromodulation Market

  • 10.1. India Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neuromodulation Market

  • 11.1. Japan Neuromodulation Market Overview
  • 11.2. Japan Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neuromodulation Market

  • 12.1. Australia Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neuromodulation Market

  • 13.1. Indonesia Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neuromodulation Market

  • 14.1. South Korea Neuromodulation Market Overview
  • 14.2. South Korea Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neuromodulation Market

  • 15.1. Western Europe Neuromodulation Market Overview
  • 15.2. Western Europe Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neuromodulation Market

  • 16.1. UK Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neuromodulation Market

  • 17.1. Germany Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neuromodulation Market

  • 18.1. France Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neuromodulation Market

  • 19.1. Italy Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neuromodulation Market

  • 20.1. Spain Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neuromodulation Market

  • 21.1. Eastern Europe Neuromodulation Market Overview
  • 21.2. Eastern Europe Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neuromodulation Market

  • 22.1. Russia Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neuromodulation Market

  • 23.1. North America Neuromodulation Market Overview
  • 23.2. North America Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neuromodulation Market

  • 24.1. USA Neuromodulation Market Overview
  • 24.2. USA Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neuromodulation Market

  • 25.1. Canada Neuromodulation Market Overview
  • 25.2. Canada Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neuromodulation Market

  • 26.1. South America Neuromodulation Market Overview
  • 26.2. South America Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neuromodulation Market

  • 27.1. Brazil Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neuromodulation Market

  • 28.1. Middle East Neuromodulation Market Overview
  • 28.2. Middle East Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neuromodulation Market

  • 29.1. Africa Neuromodulation Market Overview
  • 29.2. Africa Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neuromodulation Market Competitive Landscape And Company Profiles

  • 30.1. Neuromodulation Market Competitive Landscape
  • 30.2. Neuromodulation Market Company Profiles
    • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Soterix Medical Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Synapse Biomedical Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Neuromodulation Market Other Major And Innovative Companies

  • 31.1. Nevro Corp
  • 31.2. Neuropace Inc.
  • 31.3. LivaNova PLC
  • 31.4. Neurosigma Inc.
  • 31.5. Neuronetics Inc.
  • 31.6. Bioness Inc.
  • 31.7. Aleva Neurotherapeutics S.A.
  • 31.8. Integer Holdings Corporation
  • 31.9. ReShape Lifesciences Inc.
  • 31.10. Inspire Medical Systems Inc.
  • 31.11. Bioventus LLC
  • 31.12. Saluda Medical Pty Ltd
  • 31.13. Otolith Labs Inc.
  • 31.14. Machine Medicine Inc.
  • 31.15. Inbrain Neuroelectronics SAS

32. Global Neuromodulation Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuromodulation Market

34. Recent Developments In The Neuromodulation Market

35. Neuromodulation Market High Potential Countries, Segments and Strategies

  • 35.1 Neuromodulation Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Neuromodulation Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Neuromodulation Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer